三鑫医疗(300453) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 321,497,637.25, representing a 30.61% increase compared to CNY 246,148,032.60 in the same period last year[4] - Net profit attributable to shareholders was CNY 47,447,455.87, up 39.37% from CNY 34,044,129.84 year-on-year[4] - Basic earnings per share rose to CNY 0.1204, a 39.35% increase from CNY 0.0864 in the same period last year[4] - Total operating revenue for Q1 2022 reached ¥321,497,637.25, an increase of 30.6% compared to ¥246,148,032.60 in Q1 2021[20] - Net profit for Q1 2022 was ¥50,359,581.15, representing a 34.5% increase from ¥37,411,131.05 in Q1 2021[21] - Earnings per share for Q1 2022 were ¥0.1204, compared to ¥0.0864 in Q1 2021, reflecting a growth of 39.3%[22] Cash Flow - The net cash flow from operating activities increased by 127.00%, reaching CNY 14,868,783.06 compared to CNY 6,550,259.90 in the previous year[4] - Cash flow from operating activities in Q1 2022 was ¥350,610,682.58, an increase of 32.6% from ¥264,314,438.96 in Q1 2021[23] - The net cash flow from operating activities for Q1 2022 was ¥14,868,783.06, an increase from ¥6,550,259.90 in Q1 2021, representing a growth of approximately 127%[24] - The total cash outflow from operating activities was ¥335,741,899.52, compared to ¥257,764,179.06 in the previous year, reflecting an increase of approximately 30%[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,442,878,734.42, reflecting a 2.62% increase from CNY 1,406,039,522.12 at the end of the previous year[4] - The total liabilities decreased from CNY 379,357,648.27 to CNY 353,107,022.77, a reduction of approximately 6.9%[17] - Current assets amounted to CNY 588,432,679.18, up from CNY 548,228,432.28 at the start of the year, indicating an increase of about 7.3%[16] - The company’s long-term assets totaled CNY 854,446,055.24, slightly down from CNY 857,811,089.84 at the beginning of the year[17] - Total liabilities as of Q1 2022 were ¥406,477,102.44, a decrease from ¥427,244,790.66 in the previous year[21] Equity - The company's equity attributable to shareholders increased by 6.01%, amounting to CNY 959,968,858.03 compared to CNY 905,506,389.18 at the end of the last year[4] - Total equity attributable to shareholders of the parent company was ¥959,968,858.03, an increase of 6.0% from ¥905,506,389.18 in Q1 2021[21] Expenses - Research and development expenses increased by 72.34% to CNY 9,481,656.95, driven by increased investment in R&D projects[8] - Management expenses rose significantly by 98.56% to CNY 25,646,319.89, primarily due to increased stock incentive expenses[8] - Research and development expenses for Q1 2022 amounted to ¥9,481,656.95, up 72.5% from ¥5,501,825.94 in Q1 2021, indicating a strong focus on innovation[21] Market Strategy - The company plans to continue expanding its market presence in blood purification products, which have shown sustained revenue growth[8] - The company plans to invest CNY 568 million in a new research and production base for blood dialysis products, which is expected to enhance production capacity and support future business expansion[14] Sales Performance - The company reported a significant increase in sales collection, contributing to the rise in operating cash flow[8] - The company reported cash received from sales, totaling ¥332,918,108.44 in Q1 2022, compared to ¥250,206,117.69 in Q1 2021, reflecting strong sales performance[23]